No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MRVI Maravai LifeSciences
- 7.720
- +0.350+4.75%
Close Apr 23 16:00 ET
- 7.250
- -0.470-6.09%
Post 16:28 ET
1.02BMarket Cap-8577P/E (TTM)
8.100High7.370Low2.24MVolume7.380Open7.370Pre Close17.54MTurnover2.28%Turnover RatioLossP/E (Static)132.31MShares16.62052wk High2.45P/B760.22MFloat Cap4.52052wk Low--Dividend TTM98.47MShs Float63.550Historical High--Div YieldTTM9.91%Amplitude4.520Historical Low7.825Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego
Maravai LifeSciences Holdings' (MRVI) TriLink BioTechnologies unit said Thursday that it has opened its new, 32,000-square-foot cGMP mRNA manufacturing facility in San Diego. The facility will use Tri
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Inspire Medical Systems (INSP) and Maravai Lifesciences Holdings (MRVI)
Express News | Trilink Biotechnologies, A Maravai Lifesciences Company Opened A New 32,000 Sq.ft. MRNA Manufacturing Facility
HROW, HCAT and EGRX Are Among After Hour Movers
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
Maravai LifeSciences, Inc.(Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
Express News | Craig-Hallum Initiates Coverage On Maravai LifeSciences With Buy Rating, Announces Price Target of $15
Comments
Despite Maravai LifeSciences Holdings' significant liabilities, it has net cash, indicating a light debt load. However, its pre-interest and tax loss and declining revenue raise future earnings and balance sheet health concerns.
Is Maravai LifeSciences Holdings (NASDAQ:MRVI) Using Debt In A Risky Way? 1
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg